Research programme: antibody therapeutics - Adimab/Kodiak Sciences

Drug Profile

Research programme: antibody therapeutics - Adimab/Kodiak Sciences

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Adimab; Kodiak Sciences
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 27 Apr 2016 Early research in Undefined indication in USA (unspecified route)
  • 27 Apr 2016 Adimab and Kodiak Sciences agree to co-develop antibody-based therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top